Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$0.31 - $1.06 $817 - $2,795
-2,637 Reduced 61.54%
1,648 $1,000
Q4 2022

Feb 14, 2023

SELL
$0.27 - $11.9 $4,664 - $205,584
-17,276 Reduced 80.13%
4,285 $1,000
Q3 2022

Nov 14, 2022

BUY
$0.51 - $10.4 $10,996 - $224,234
21,561 New
21,561 $11,000
Q1 2022

May 16, 2022

SELL
$0.93 - $1.29 $22,011 - $30,531
-23,668 Reduced 65.52%
12,453 $16,000
Q4 2021

Feb 14, 2022

BUY
$1.14 - $1.58 $10,980 - $15,218
9,632 Added 36.36%
36,121 $41,000
Q3 2021

Nov 15, 2021

SELL
$1.39 - $2.1 $43,256 - $65,352
-31,120 Reduced 54.02%
26,489 $40,000
Q2 2021

Aug 16, 2021

BUY
$1.56 - $2.26 $47,263 - $68,471
30,297 Added 110.93%
57,609 $114,000
Q1 2021

May 17, 2021

BUY
$1.77 - $2.98 $28,732 - $48,374
16,233 Added 146.52%
27,312 $50,000
Q4 2020

Feb 16, 2021

SELL
$1.58 - $3.64 $14,588 - $33,608
-9,233 Reduced 45.46%
11,079 $24,000
Q3 2020

Nov 16, 2020

BUY
$2.84 - $4.59 $57,686 - $93,232
20,312 New
20,312 $63,000

About Hepion Pharmaceuticals, Inc.


  • Ticker HEPA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,229,600
  • Market Cap $51.8M
  • Description
  • Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...
More about HEPA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.